Volume 88, Issue 1 pp. 115-120
Cancer Therapy

An entirely humanized CD3 ζ-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells

Andreas Hombach

Andreas Hombach

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Search for more papers by this author
Claudia Schneider

Claudia Schneider

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Search for more papers by this author
Dagmar Sent

Dagmar Sent

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Search for more papers by this author
Dimitra Koch

Dimitra Koch

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Search for more papers by this author
Ralph A. Willemsen

Ralph A. Willemsen

Department of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

Search for more papers by this author
Volker Diehl

Volker Diehl

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Search for more papers by this author
Wolfgang Kruis

Wolfgang Kruis

Evangelisches Krankenhaus Köln-Kalk, Köln, Germany

Search for more papers by this author
Reinder L. Bolhuis

Reinder L. Bolhuis

Department of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

Search for more papers by this author
Christoph Pohl

Christoph Pohl

Evangelisches Krankenhaus Köln-Kalk, Köln, Germany

Search for more papers by this author
Hinrich Abken

Corresponding Author

Hinrich Abken

Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany

Klinik I für Innere Medizin, Labor für Tumorgenetik, Universität zu Köln, Josef-Stelzmann-Str. 9, D-50924 Köln, Germany. Fax: +49 221 478 4130Search for more papers by this author

Abstract

Recombinant T-cell receptors with antibody-like specificity for tumor-associated antigens are successfully used to direct the cytolytic activity of T cells toward tumor cells. Clinical application, however, needs to comply with the low immunogenicity of the recombinant receptor, efficient gene transfer into peripheral blood T cells, and enrichment of receptor-grafted cells. Here, we address these issues and describe an entirely humanized immune receptor for use in adoptive immunotherapy of colorectal carcinoma. The receptor consists of a single-chain antibody (scFv) binding domain specific for carcinoembryonic antigen (CEA), the IgG hinge and CH2/CH3 (Fc) joining region, and the transmembrane and intracellular CD3 ζ signaling chain. To express the receptor in peripheral blood T cells, both GALV envelope and MuLV 4070A pseudotyped retrovirus turned out to be equally efficient, with transduction efficiencies of about 5% to 40%, depending on the lymphocyte donor. Furthermore, receptor-grafted T cells could be 2- to 6-fold enriched by magnetic activated cell sorting, utilizing an antibody directed to the extracellular IgG domain of the receptor. Upon co-culture with CEA+ tumor cells, receptor-grafted T cells are specifically and efficiently activated to cytolysis and IFN-γ secretion, demonstrating their feasibility for the adoptive immunotherapy of CEA+ carcinomas. Int. J. Cancer 88:115–120, 2000. © 2000 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.